Breakfast Technical Briefing on NovoCure and Three Other Additional Medical Equipment Stocks

Stock Research Monitor: LNTH, NVRO, and NUVA

LONDON, UK / ACCESSWIRE / May 31, 2018/ If you want a free Stock Review on NVCR sign up now at www.wallstequities.com/registration. WallStEquities.com has selected the following Medical Appliances and Equipment stocks for review this morning: Lantheus Holdings Inc. (NASDAQ: LNTH), Nevro Corp. (NYSE: NVRO), NovoCure Ltd (NASDAQ: NVCR), and NuVasive Inc. (NASDAQ: NUVA). These companies are part of the Healthcare sector, which received an “Outperform” rating from Charles Schwab on May 24th, 2018, generally because of solid balance sheets, attractive dividend yields, and the appearance of an improved overall cost structure. All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Lantheus Holdings

North Billerica, Massachusetts headquartered Lantheus Holdings Inc.’s shares gained slightly by 0.35%, closing Wednesday’s trading session at $14.20. The stock recorded a trading volume of 348,935 million shares. The Company’s shares are trading 10.27% below their 50-day moving average. Additionally, shares of Lantheus, which develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide, have a Relative Strength Index (RSI) of 41.30.

On May 23rd, 2018, Lantheus announced that Mary Anne Heino, President and CEO, and Jack Crowley, CFO, will present at the Jefferies 2018 Global Healthcare Conference on June 05th, 2018, at 9:30 a.m. ET in New York. A live webcast of the presentation will be available under the Investors section of the Company’s website. Get the full research report on LNTH for free by clicking below at:

www.wallstequities.com/registration/?symbol=LNTH

Nevro

On Wednesday, shares in Redwood City, California headquartered Nevro Corp. recorded a trading volume of 438,339 shares. The stock rose slightly by 0.23%, ending the day at $78.49. The Company’s shares have advanced 10.55% over the past year. The stock is trading below its 200-day moving average by 4.64%. Furthermore, shares of Nevro, which provides products for the patients suffering from chronic pain in the US and internationally, have an RSI of 47.82.

On May 08th, 2018, research firm Canaccord Genuity reiterated its ‘Buy’ rating on the Company’s stock with a decrease of the target price from $110 a share to $102 a share.

On May 14th, 2018, Nevro announced that it has been named one of the “Best Places to Work” in the Bay Area by the San Francisco Business Times and the Silicon Valley Business Journal. Select employers from the Bay Area were named winners of the awards program that is held annually. These winning organizations were honored for creating exceptional workplaces that their employees value highly. NVRO’s complimentary research coverage is a few simple steps away at:

www.wallstequities.com/registration/?symbol=NVRO

NovoCure

NovoCure Ltd’s stock finished the day 2.35% higher at $31.52 with a total trading volume of 769,255 shares. The Company’s shares have advanced 15.48% in the last month, 53.41% in the previous three months, and 152.20% over the past year. The stock is trading above its 50-day and 200-day moving averages by 25.28% and 46.81%, respectively. Additionally, shares of NovoCure, which markets a wearable electric field device for treating glioblastoma brain cancer, have an RSI of 78.71. Register for your free research report on NVCR at:

www.wallstequities.com/registration/?symbol=NVCR

NuVasive

Shares in San Diego, California headquartered NuVasive Inc. ended yesterday’s session 1.52% higher at $50.87. The stock recorded a trading volume of 324,411 shares. The Company’s shares have advanced 5.19% over the previous three months. The stock is trading 1.65% below its 50-day moving average. Moreover, shares of NuVasive, which develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery, have an RSI of 52.33.

On May 02nd, 2018, research firm Needham reiterated its ‘Buy’ rating on the Company’s stock with a decrease of the target price from $70 a share to $69 a share.

On May 23rd, 2018, NuVasive announced that the Company’s SpineTRACK Registry has reached a significant enrollment milestone of 10,000 patients from more than 50 surgeons in the United States since its inception in 2011. The SpineTRACK Registry is a Company-sponsored quality improvement tool that tracks patient outcomes through their treatment and recovery. Wall St. Equities’ downloadable research report on NUVA available at:

www.wallstequities.com/registration/?symbol=NUVA

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

ReleaseID: 501357